ORALONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORALONE (ORALONE).
ORALONE is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory cytokines.
| Metabolism | ORALONE is primarily metabolized in the liver via CYP3A4 to inactive metabolites, which are excreted in urine and bile. |
| Excretion | Renal: >90% as glucuronide conjugates and unchanged drug (approximately 60% as metabolites, 30% unchanged). Biliary/fecal: <5%. |
| Half-life | 1.5–3 hours (mean 2.5 hours) in adults; prolonged to 3–6 hours in hepatic impairment and up to 4 hours in elderly patients. |
| Protein binding | 70–80% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 0.4–0.6 L/kg (approximately 30–40 L in a 70 kg adult), indicating moderate tissue distribution. |
| Bioavailability | Oral: 60–75% (first-pass metabolism reduces systemic availability). Topical mucosal: variable but higher local absorption; systemic absorption <1%. |
| Onset of Action | Oral: 30–60 minutes to initial clinical effect; peak effect at 1–2 hours. Topical (mucosal): within 5–15 minutes. |
| Duration of Action | 4–6 hours for oral formulation; topical mucosal effect lasts 2–3 hours after a single application. |
| Molecular Weight | 360.44 |
0.3-0.6 mg/kg IV/IM every 4-6 hours as needed; maximum single dose 30 mg.
| Dosage form | PASTE |
| Renal impairment | CrCl 30-60 mL/min: reduce dose by 25%; CrCl <30 mL/min: reduce dose by 50% and extend interval to every 8 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use. |
| Pediatric use | Children <6 months: 0.1-0.2 mg/kg IV/IM every 4-6 hours; 6 months-12 years: 0.2-0.5 mg/kg IV/IM every 4-6 hours; maximum single dose 15 mg. |
| Geriatric use | Reduce initial dose by 50% (maximum 15 mg per dose) and titrate cautiously due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Avoid due to risk of cleft palate and congenital anomalies based on animal studies and limited human data. |
| 2nd trimester | Use only if benefit outweighs risk; may cause fetal adrenal suppression and growth restriction. |
| 3rd trimester | Avoid due to risk of neonatal adrenal suppression, hypoglycemia, and immunosuppression. |
Clinical note
Comprehensive clinical and safety monograph for ORALONE (ORALONE).
| Placental transfer | Crosses placenta readily; metabolized by placental 11β-HSD2 but fetal levels still significant. |
| Breastfeeding | Enters breast milk in low amounts; use with caution, especially with high doses or prolonged therapy. Monitor infant for signs of adrenal suppression. |
| Lactation Rating |
■ FDA Black Box Warning
No black box warning has been issued for ORALONE.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to any componentConcurrent live or live-attenuated vaccines
| Precautions | Systemic absorption may occur with prolonged use on large areas or under occlusive dressings., Local adverse reactions include burning, itching, irritation, dryness, and atrophy., Avoid use in the presence of untreated bacterial, viral, or fungal infections., Use with caution in patients with a history of hypersensitivity to corticosteroids. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase systemic exposure. Limit sodium intake to reduce fluid retention. Maintain adequate calcium and vitamin D intake to prevent bone loss. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | ORALONE (prednisolone) is a corticosteroid. First trimester: Increased risk of cleft palate (OR 3.4, 95% CI 1.5-7.7) with systemic use; risk is dose-dependent. Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Avoid high doses during pregnancy if possible. |
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, signs of infection, and adrenal function. Fetal monitoring for growth restriction via ultrasound; assess for preterm labor symptoms. In neonates: observe for hypoglycemia, hypoadrenalism. |
| Fertility Effects | High-dose corticosteroids may disrupt menstrual cycle and ovulation via suppression of hypothalamic-pituitary-ovarian axis, but reversible upon dose reduction. No evidence of permanent infertility. |
| Clinical Pearls | ORALONE (hydrocortisone) is a corticosteroid used for anti-inflammatory and immunosuppressive effects. Monitor for signs of adrenal suppression with prolonged use. Taper dose gradually to avoid withdrawal. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease. Avoid live vaccines during therapy. |
| Patient Advice | Take exactly as prescribed; do not abruptly stop medication. · May cause increased appetite, weight gain, or fluid retention. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding. · Avoid grapefruit and grapefruit juice. · Carry a medical alert card indicating corticosteroid use. · Do not receive live vaccines while on this medication. |